Log In
Print this Print this

Semprana, dihydroergotamine (formerly Levadex, MAP0004)

  Manage Alerts
Collapse Summary General Information
Company Allergan plc
DescriptionDihydroergotamine (DHE) mesylate compound that agonizes the serotonin (5-HT) receptor and is delivered via Map's Tempo Inhaler
Molecular Target Serotonin (5-HT1D) receptor
Mechanism of ActionSerotonin (5-HT1D) receptor agonist
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentRegistration
Standard IndicationMigraine
Indication DetailsTreat acute migraine; Treat acute migraine in patients with compromised lung function
Regulatory Designation U.S. - Undisclosed Review (Treat acute migraine)
PartnerNektar Therapeutics

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments





 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone









Get a free BioCentury trial today